399-30-4

Usage

Uses

Used in Pharmaceutical Industry:
(2-FLUOROBENZYL)METHYLAMINE is used as a pharmaceutical intermediate for the development of drugs with specific therapeutic applications. Its unique structure allows for the creation of molecules with tailored properties, making it a versatile component in drug design.
Used in Medicinal Chemistry:
(2-FLUOROBENZYL)METHYLAMINE is used as a reactant in the preparation of biologically and pharmacologically active molecules. Its presence in these molecules can influence their binding affinity, selectivity, and overall pharmacological profile, contributing to the development of novel therapeutic agents.

InChI:InChI=1/C8H10FN/c1-10-6-7-4-2-3-5-8(7)9/h2-5,10H,6H2,1H3

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 
• 446-52-6 2-Fluorobenzaldehyde 
• 345-35-7 2-fluorobenzyl chloride 
• 89-99-6 2-fluorobenzylamine 
• 1159505-61-9 C₈H₇F₄NO₂S 
• 36457-58-6 N-benzyl-1,1,1-trifluoromethanesulfonamide 
• 100-46-9 benzylamine 
• 1159505-77-7 C₉H₉F₄NO₂S 
• 153903-21-0 N-(tert-butyloxycarbonyl)-2-fluorobenzylamine 

Downstream Products

• 957113-03-0 C₃₄H₄₃F₂N₃O₆ 
• 1092060-54-2 C₂₅H₂₄F₂N₂ 
• 1092060-66-6 C₂₆H₂₆F₂N₂ 
• 1174903-49-1 3-[[(2-fluorobenzyl)-methyl-amino]methyl]-5-(pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one 
• 866782-13-0 [1-(R)-{[(2-fluoro-benzyl)-methyl-carbamoyl]-methyl}-2-(2-fluoro-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1426842-05-8 C₁₈H₁₈FN₃O₆S 
• 1426842-47-8 C₂₀H₂₂FN₃O₆S 
• 952492-80-7 3-(3,3-dimethyl-1-oxoisochroman-4-yl)-3H-imidazole-4-carboxylic acid (2-fluorobenzyl)methylamide 

Relevant academic research and scientific papers

NECROSIS INHIBITORS

The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

PALLADIUM-CATALYZED ORTHO-FLUORINATION

A new method of ortho-fluorination where an aryl C—H bond is directly replaced by an aryl C-F bond in a palladium-catalyzed reaction is provided. The method includes the ortho-fluorination of a triflamide protected benzylamine, a palladium catalyst, such as Pd(OTf)2, a fluorinating reagent such as N-fluoro-2,4,6-trimethylpyridinium triflate, and a ligand to promote the reaction such as N-methylpyrrolidinone (NMP).

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

Versatile Pd(OTf)2·2H2O-catalyzed ortho-fluorination using NMP as a promoter

(Chemical Equation Presented) Pd(OTf)2·2H 2O-catalyzed ortho-fluorination of triflamide-protected benzylamines is reported. The use of N-fluoro-2,4,6-trimethylpyridinium triflate as the F+ source and NMP as a promoter is crucial for this reaction. The conversion of triflamide into a wide range of synthetically useful functional groups makes this fluorination protocol broadly applicable in medicinal chemistry and synthesis.

Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations

3H-1,3,4-Oxadiazol-2-one derivatives were synthesized and tested for their in vitro antimycobacterial activity. Oxadiazolone derivatives showed an interesting antimycobacterial activity against the reference strain of Mycobacterium tuberculosis H37Rv. Molecular modeling investigations were performed and showed that the active compounds possess all necessary features to target the protein active site of the mycobacterial cytochrome P450-dependent sterol 14α-demethylase in the sterol biosynthesis pathway as the calculated free energy of binding were in agreement with the corresponding MIC values.

DPP-IV INHIBITORS

The invention relates to compounds of formula (I), Z-C(R1R 2)-C(R3NH2)-C(R4R5)-X-N(R 6R7), wherein Z, R1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

Facile preparation of N-methyl secondary amines by titanium(IV) isopropoxide-mediated reductive animation of carbonyl compounds

A simple, mild and efficient procedure for obtaining N-methyl secondary amines from aldehydes and ketones is reported. Treatment of carbonyl compounds with methylamine hydrochloride, triethylamine and titanium(IV) isopropoxide, followed by in situ sodium borohydride reduction and straightforward aqueous work-up, affords clean products in good to excellent yields.